Whole body staging can miss melanoma and lung mets

Oncology NEWS InternationalOncology NEWS International Vol 17 No 2
Volume 17
Issue 2

In a surprising discovery, reported at RSNA 2007, researchers from Germany have found that whole-body staging of patients with recently diagnosed malignant melanoma using either MRI or PET/CT could miss a substantial number of metastatic lesions

CHICAGO—In a surprising discovery, reported at RSNA 2007, researchers from Germany have found that whole-body staging of patients with recently diagnosed malignant melanoma using either MRI or PET/CT could miss a substantial number of metastatic lesions (see cover art).

More than 50,000 US patients will be diagnosed each year with melanoma, according to the National Cancer Institute. The disease is usually confined within a skin lesion but can spread through the body during advanced stages. Good prognosis depends on accurate tumor staging, which is done with CT, MRI, ultrasound, or scintigraphy.

The whole-body exam has recently been recognized as the most accurate for staging. Radiologists must be aware, however, that regional or lymph node metastases could appear within a few months of the resection of a melanoma, and they cannot trust blindly in the primary imaging performed immediately after surgery, said Florian Vogt, MD, of the Department of Diagnostic and Interventional Radiology at the University Hospital of Essen.

"You should always scan these patients at least a couple of times within 1 year of the primary staging. There might be future metastases, so these patients need long-term follow-up," Dr. Vogt said in an interview.

Dr. Vogt and colleagues enrolled 60 consecutive patients who underwent whole-body 1.5T MRI and whole-body FDG-PET/CT for staging of regional lymph nodes (N) and distant metastases (M) after primary tumor resection. The investigators followed the American Joint Committee on Cancer Staging guidelines for tumor classification and used biopsy and clinical follow-up as gold standards.

Two radiologists interpreted MR images, while PET/CT scans were read by one radiologist and one nuclear physician; 56 patients completed the mean follow-up of 748 days.

Undetected metastases

The researchers found that a significant number of patients initially staged as N-negative and M-negative with whole-body MRI and whole-body PET/CT eventually proved to have undetected regional or distant metastases.

Whole-body MRI and whole-body PET/CT determined regional lymph node involvement correctly in 46 and 48 cases, respectively.

N-staging with whole-body MRI yielded a specificity of 100% but a sensitivity of only 23%. Regional lymph node staging with whole-body PET/CT fared only slightly better, with specificity and sensitivity values of 100% and 38.5%, respectively.

The M-stage was diagnosed correctly in 42 patients with whole-body MRI and in 46 with PET/CT.

Of 56 patients who underwent staging for distant metastases with PET/CT, 3 were confirmed as false positives and 7 turned into false negatives (sensitivity 41.7% and specificity 93.2%). With whole-body MRI, the M-stage yielded 3 false positives and 11 false negatives (sensitivity 15.4% and specificity 93%).

NSCLC bone metastases

Another research team from Essen also evaluated the accuracy of whole-body FDG-PET/CT and whole-body MRI for the staging and detection of bone metastases in patients with a recent diagnosis of melanoma or non-small-cell lung cancer (NSCLC) (see Figure on page 50).

Gerald Antoch, MD, and his colleagues assessed 109 patients, 55 with melanoma and 54 with NSCLC.

Patients underwent whole-body staging with contrast-enhanced FDG-PET/CT. Patients also underwent nonenhanced T1/T2 and contrast-enhanced T1-weighted whole-body MRI within a mean time interval of 0.6 days of a PET/CT scan.

A nuclear medicine physician and a radiologist read PET/CT and MRI studies, respectively, in a blinded fashion. Researchers also used histopathology and clinical follow-up (mean, 434 days) as the standards of reference.

False-negative results

The investigators found whole-body PET/CT and whole-body MRI similarly accurate for staging and detection of bone metastases.

They also observed a significant rate of false negatives, however, particularly with whole-body MRI, although the difference was not statistically significant when compared with whole-body PET/CT, Dr. Antoch said.

"There is a substantial number of false-negative findings if you perform the two imaging procedures at diagnosis of the patient. That really requires a close follow-up of these patients," Dr. Antoch commented.

Both investigators said that the papers require validation by larger population studies.

Related Videos
Experts on myeloma
In terms of tumor control, treatment with cabozantinib and atezolizumab led to an overall response rate of 19% among patients with advanced non–small cell lung cancer, according to Joel W. Neal, MD, PhD.
Experts on lung cancer
Expert on lung cancer
Expert on lung cancer
Expert on lung cancer
Experts on lung cancer
Expert on lung cancer
Expert on lung cancer
Related Content